MedPath

Henrik Gregersen

🇩🇰Denmark
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

4

Active:0
Completed:0

Trial Phases

2 Phases

Early Phase 1:1
Phase 2:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 2
3 (75.0%)
Early Phase 1
1 (25.0%)

Clarithromycin, Sulfamethoxazole/Trimethoprim or Observation in Newly Diagnosed Multiple Myeloma

Phase 2
Conditions
Multiple Myeloma
Infection
Interventions
Drug: Standard myeloma treatment
Drug: Observation
First Posted Date
2015-12-08
Last Posted Date
2015-12-08
Lead Sponsor
Henrik Gregersen
Target Recruit Count
300
Registration Number
NCT02624440
Locations
🇩🇰

Department of Hematology, Aalborg University Hospital, Aalborg, Denmark

🇩🇰

Department of Hematology, Aarhus University Hospital, Aarhus, Denmark

🇩🇰

Department of Hematology, Rigshospitalet, Copenhagen, Denmark

and more 5 locations

Clarithromycin in Multiple Myeloma Induction Therapy

Phase 2
Terminated
Conditions
Multiple Myeloma
Interventions
Drug: Placebo
Drug: VCD induction therapy
First Posted Date
2015-10-12
Last Posted Date
2016-09-20
Lead Sponsor
Henrik Gregersen
Target Recruit Count
58
Registration Number
NCT02573935
Locations
🇩🇰

Department of Hematology, Aalborg University Hospital, Aalborg, Denmark

🇩🇰

Department of Hematology, Aarhus University Hospital, Aarhus, Denmark

🇩🇰

Department of Hematology, Rigshospitalet, Copenhagen, Denmark

and more 4 locations

Study of Carfilzomib in Multiple Myeloma Relapsed After High-dose Melphalan With Autologous Stem Cell Support

Phase 2
Conditions
Multiple Myeloma
Interventions
Drug: Induction with CAR-CY-DEX and conditioning with carfilzomib and highdose melphalan
Drug: Carfilzomib/dexamethasone maintenance
Drug: Observation without carfilzomib/dexamethasone maintenance
First Posted Date
2015-10-09
Last Posted Date
2018-08-17
Lead Sponsor
Henrik Gregersen
Target Recruit Count
200
Registration Number
NCT02572492
Locations
🇩🇰

Aalborg University Hospital, Aalborg, Denmark

🇫🇮

Turku University Hospital, Turku, Finland

🇱🇹

Vilnius University hospital "Santariskiu Clinics", Vilnius, Lithuania

and more 2 locations

Microdose Study of Melphalan, Bortezomib and Dexamethasone

Early Phase 1
Conditions
Multiple Myeloma
Interventions
First Posted Date
2014-04-10
Last Posted Date
2015-12-08
Lead Sponsor
Henrik Gregersen
Target Recruit Count
6
Registration Number
NCT02109861
Locations
🇩🇰

Department of Haematology, Aalborg University Hospital, Aalborg, Denmark

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.